Print this Page for Your Records | Close Window

Control/Tracking Number: 2012-A-3482-Diabetes
Activity: Abstract
Current Date/Time: 1/30/2012 7:10:09 AM

The Cost and Productivity Consequences of Non-Severe Hypoglycaemic Episodes (NSHE) in Patients Receiving Sulfonylurea or DPP4 Dual Combination Oral Therapy

Author Block: PHIL MCEWAN, MARC EVANS, VOLKER FOOS, ADAM LLOYD, DAVID GRANT, Swansea, United Kingdom, Cardiff, United Kingdom, Basel, Switzerland, London, United Kingdom

Abstract:
Hypoglycemia is a major consideration in the management of blood glucose in people with type 2 diabetes. NSHE occur more frequently than severe episodes and account for the majority of hypoglycemic burden. Recent data has quantified the per-event cost of NSHE in terms of productivity loss and out-of-pocket expenses. The aim of this study was to model the cost implications for NSHE in relation to sulfonylurea or DPP-4 based dual combination blood glucose lowering regimens
Published patient source data was used to obtain workplace productivity costs, out-of-pocket (OOP) expenses and estimates of the frequency of NSHE. The IMS CORE Diabetes Model (CDM) a validated and widely used simulation model was initiated with dual therapy patient profiles derived from NHANES and efficacy profiles for metformin + sulfonylurea (M+S) versus metformin + DPP-4 (M+D) obtained via a mixed treatment comparison. Costs (2010) and benefits are in USD and discounted at 3%.
In the published patient source data mean weighted productivity cost of each NSHE was $34.87 with monthly OOP of $35.56; at a frequency of 1 NSHE per week M+D is associated with an incremental annual cost of $212 compared to M+S after including the expected annual $2,240 cost offset associated with productivity and OOP expenses. Over a lifetime, the discounted cost per quality adjusted life year gained for M+D versus M+S was $2,419
Sulfonylurea based dual combination therapy is potentially associated with greater economic consequences for employers and patients compared with DPP-4 based dual therapy regimens. Therefore greater consideration should be given to the productivity related consequences of hypoglycemia with respect to dual therapy escalation, particularly in people with type 2 diabetes of a working age.
:

Category (Complete):  13 Health Care Delivery - Economics
Presentation Preference (Complete):  No Preference
Sponsor (Complete):
* At least one (1) author listed on this abstract is a current member of the ADA and therefore a sponsor is not required.: Yes

Financial Support (Complete):
* ADA Support: No

Keywords (Complete):  hypoglycemia cost ; burden
Payment (Complete): Your credit card order has been processed on Thursday 5 January 2012 at 10:49 AM.
Status: Complete

American Diabetes Association
1701 North Beauregard Street
Alexandria, VA 22311
Questions about abstracts?
Contact the ADA at
[email-masked]

Powered by OASIS, The Online Abstract Submission and Invitation System SM
© 1996 - 2012 Coe-Truman Technologies, Inc. All rights reserved.